ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2017
Functional Optical Imaging of Primary Human Tumor Organoids: Development of a Personalized Drug Screen.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- Coculture of tumor organoids with pathogenic microorganisms: a novel system to mimicFrontiers in cellular and infection microbiology · 2025Review
- Harnessing the power of artificial intelligence for human living organoid research.Bioactive materials · 2024Review
- Insights into metabolic heterogeneity of colorectal cancer gained from fluorescence lifetime imaging.eLife · 2024Article
- The Transformative Role of 3D Culture Models in Triple-Negative Breast Cancer Research.Cancers · 2024Review
- Cancer organoids: A platform in basic and translational research.Genes & diseases · 2024Review
- Establishment and characterization of a sigmoid colon cancer organoid with spinal metastasis.Frontiers in cell and developmental biology · 2024Article
- Preclinical Models of Low-Grade Gliomas.Cancers · 2023Review
- Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today?Cancers · 2022Review
- Technologies to Assess Drug Response and Heterogeneity in Patient-Derived Cancer Organoids.Annual review of biomedical engineering · 2022Review
- Microphysiological model of renal cell carcinoma to inform anti-angiogenic therapy.Biomaterials · 2022Article
- Establishment of patient-derived organoid models of lower-grade glioma.Neuro-oncology · 2022Article
- Clinical translation of patient-derived tumour organoids- bottlenecks and strategies.Biomarker research · 2022Review
- Mesoscopic fluorescence lifetime imaging: Fundamental principles, clinical applications and future directions.Journal of biophotonics · 2021Review
- The Progress and Clinical Application of Breast Cancer Organoids.International journal of stem cells · 2020Review
- Kinetic Analysis of Lipid Metabolism in Breast Cancer Cells via Nonlinear Optical Microscopy.Biophysical journal · 2020Article
- Progress in the application of organoids to breast cancer research.Journal of cellular and molecular medicine · 2020Review
- Human Colon Organoids and Other Laboratory Strategies to Enhance Patient Treatment Selection.Current treatment options in oncology · 2020Review
- SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.Theranostics · 2020Article
- Cellular Metabolic Heterogeneity In Vivo Is Recapitulated in Tumor Organoids.Neoplasia (New York, N.Y.) · 2019Article
- Harnessing the Power of Optical Microscopic and Macroscopic Imaging for Natural Products as Cancer Therapeutics.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Primary tumor organoids are a robust model of individual human cancers and present a unique platform for patient-specific drug testing. Optical imaging is uniquely suited to assess organoid function and behavior because of its subcellular resolution, penetration depth through the entire organoid, and functional endpoints. Specifically, optical metabolic imaging (OMI) is highly sensitive to drug response in organoids, and OMI in tumor organoids correlates with primary tumor drug response. Therefore, an OMI organoid drug screen could enable accurate testing of drug response for individualized cancer treatment. The objective of this perspective is to introduce OMI and tumor organoids to a general audience in order to foster the adoption of these techniques in diverse clinical and laboratory settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.